Skip to main content
Clinical Trials/JPRN-UMIN000044642
JPRN-UMIN000044642
Completed
未知

Study of the influence of prolonged administration of topiroxostat and control of serum uric acid level on renal function in hyperuricemia patients - Top real

Medical corporation jyosuikai Shimada hospital Hidetaka Shimada0 sites75 target enrollmentJune 24, 2021
ConditionsHyperuricemia

Overview

Phase
未知
Intervention
Not specified
Conditions
Hyperuricemia
Sponsor
Medical corporation jyosuikai Shimada hospital Hidetaka Shimada
Enrollment
75
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 24, 2021
End Date
April 30, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Medical corporation jyosuikai Shimada hospital Hidetaka Shimada

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • \[Exclusion criteria] (1\) Patients with AST or ALT 100 IU/L or higher at the start of topiroxostat treatment (2\) Patients with eGFR \< 30 at the start of topiroxostat treatment (3\) Patients receiving hemodialysis at the start of topiroxostat treatment or those who underwent kidney transplantation (4\) Patients with viral hepatitis, chronic liver disease, or malignancy at the start of topiroxostat treatment (5\) Patients considered inappropriate for participation in the study by the investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials